A review of targeted therapies for anemia in patients with lower-risk myelodysplastic syndromes and myelofibrosis that improve transfusion independence and hemoglobin levels.

New-onset type 2 diabetes was linked to an increased risk for developing certain cancers typically related to obesity, ...

Editas Medicine struggles with underwhelming data and lacks major partnerships. Find out why EDIT stock faces significant ...

Q4 2024 Earnings Call Transcript March 31, 2025 Omeros Corporation beats earnings expectations. Reported EPS is $-0.54, ...

SEATTLE, WA, USA I March 21, 2025 I Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating ...

Colorectal cancer is a serious but preventable disease if detected early. Advances in diagnostics, such as biomarker analysis ...

Zaltenibart is Omeros’ investigational inhibitor of MASP-3, the key and most proximal activator of the alternative pathway of complement ... extravascular hemolysis while achieving gender-normal ...

Implementing artificial intelligence (AI) has transformed clinicians' and health systems' ability to screen for and distinguish forms of cardiorenalmetabolic disease.

Paid Advertisement Methylene blue has gained widespread attention for its potential effects on focus, mood, and energy.